RNA Vaccines

Abstract

The present invention relates to an RNA vaccine comprising an RNA molecule encoding an allergen or derivative thereof and uses thereof.

1 . RNA vaccine comprising at least one RNA molecule encoding for at least one allergen or derivative thereof, wherein said allergen is an allergen of  Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba  and  Phleum pratense.    
     
     
         2 . Vaccine according to  claim 1 , characterised in that the allergen of  Alnus glutinosa  is Aln g 1, the allergen of  Alternaria alternata  is selected from the group consisting of Alt a 1, Alt a 3, Alt a 4, Alt a 5, Alt a 6, Alt a 7, Alt a 8, Alt a 10, Alt a 12 and Alt a 13, the allergen of  Ambrosia artemisiifolia  is selected from the group consisting of Amb a 1, Amb a 2, Amb a 3, Amb a 5, Amb a 6, Amb a 7, Amb a 8, Amb a 9 and Amb a 10, the allergen of  Apium graveolens  is selected from the group consisting of Api g 1, Api g 4 and Api g 5, the allergen of  Arachis hypogaea  is selected from the group consisting of Ara h 1, Ara h 2, Ara h 3, Ara h 4, Ara h 5, Ara h 6, Ara h 7 and Ara h 8, the allergen of  Betula verrucosa  is selected from the group consisting of Bet v 1, Bet v 2, Bet v 3, Bet v 4, Bet v 6 and Bet v 7, the allergen of  Carpinus betulus  is Car b 1, the allergen of  Castanea sativa  is selected from the group consisting of Cas s 1, Cas s 5 and Cas s 8, the allergen of  Cladosporium herbarum  is selected from the group consisting of CIa h 2, CIa h 5, CIa h 6, CIa h 7, CIa h 8, CIa h 9, CIa h 10 and CIa h 12, the allergen of  Corylus avellana  is selected from the group consisting of Cor a 1, Cor a 2, Cor a 8, Cor a 9, Cor a 10 and Cor a 11, the allergen of  Cryptomeria japonica  is selected from the group consisting of Cry j 1 and Cry j 2, the allergen of  Cyprinus carpio  is Cyp c 1, the allergen of  Daucus carota  is selected from the group consisting of Dau c 1 and Dau c 4, the allergen of  Dermatophagoides pteronyssinus  is selected from the group consisting of Der p 1, Der p 2, Der p 3, Der p 4, Der p 5, Der p 6, Der p 7, Der p 8, Der p 9, Der p 10, Der p 11, Der p 14, Der p 20, Der p 21 and Clone 30 allergen, the allergen of  Fagus sylvatica  is Fag s 1, the allergen of  Felis domesticus  is selected from the group consisting of Fel d 1, Fel d 2, Fel d 3, Fel d 4, Fel d 5w, Fel d 6w and Fel d 7w, the allergen of  Hevea brasiliensis  is selected from the group consisting of Hey b 1, Hey b 2, Hey b 3, Hey b 4, Hey b 5, Hey b 6.01, Hey b 6.02, Hey b 6.03, Hey b 7.01, Hey b 7.02, Hey b 8, Hey b 9, Hey b 10, Hey b 11, Hey b 12 and Hey b 13, the allergen of  Juniperus ashei  is selected from the group consisting of Jun a 1, Jun a 2 and Jun a 3, the allergen of  Malus domestica  is selected from the group consisting of Mal d 1, Mal d 2, Mal d 3 and Mal d 4, the allergen of  Quercus alba  is Que a 1 and the allergen of  Phleum pratense  is selected from the group consisting of PhI p 1, PhI P 2, PhI P 4, PhI P 5, PhI P 6, PhI P 7, PhI P 11, PhI P 12 and PhI p 13. 
     
     
         3 . Vaccine according to  claim 1 , characterised in that the allergen is selected from the group consisting of Aln g 1, Alt a 1, Amb a 1, Api g 1, Ara h 2, Bet v 1, beta-casein, Car b 1, Cas s 1, CIa h 8, Coral, Cry j 1, Cyp c 1, Dau c 1, Der p 2, Fag s 1, Fel d 1, Hey b 6, Jun a 1, Mal d 1, ovalbumin (OVA), PhI P 1, PhI P 2, PhI P 5, PhI P 6 and PhI p 7. 
     
     
         4 . Vaccine according to  claim 1 , characterised in that the RNA molecule encodes for PhI p 1, PhI P 2, PhI P 5 and PhI p6, or for Aln g 1, Cor a 1, Que a 1, Car bland Bet v 1. 
     
     
         5 . Vaccine according to  claim 1 , characterized in that the allergen derivative is hypoallergenic. 
     
     
         6 . Vaccine according to  claim 5 , characterised in that the hypoallergenic allergen derivative exhibits an IgE reactivity which is at least 10%, preferably at least 20%, more preferably at least 30%, in particular at least 50%, lower than the IgE reactivity of the wild-type allergen. 
     
     
         7 . Vaccine according to  claim 1 , characterized in that the RNA molecule encoding the allergen or derivative thereof is fused to at least one further molecule encoding a peptide, polypeptide or protein. 
     
     
         8 . Vaccine according to  claim 1 , characterized in that the RNA molecule comprises at least one further element selected from the group consisting of replicase, G-globin leader sequence, capO, cap1 and poly A tail. 
     
     
         9 . Vaccine according to  claim 1 , characterized in that the vaccine comprises further an adjuvant, preferably selected from the group consisting of CpG-DNA and cytokines, preferably IL-12 and IL-15. 
     
     
         10 . Vaccine according to  claim 1 , characterized in that the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration. 
     
     
         11 . Use of at least one RNA molecule as defined in  claim 1  for the manufacture of a vaccine for treating or preventing allergy. 
     
     
         12 . Use of at least one RNA molecule as defined in  claim 1  for the manufacture of a protective and therapeutic vaccine for hyposensitising an individual to an allergen. 
     
     
         13 . Use according to  claim 11 , characterised in that the vaccine comprises further an adjuvant, preferably selected from the group consisting of CpG-DNA and cytokines, preferably IL-12 and IL-15. 
     
     
         14 . Use according to anyone of  claim 11 , characterized in that the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration. 
     
     
         15 . Isolated RNA molecule comprising at least one nucleotide sequence encoding at least one allergen or derivative thereof as defined in  claim 1 . 
     
     
         16 . Use according to  claim 12 , characterised in that the vaccine comprises further an adjuvant, preferably selected from the group consisting of CpG-DNA and cytokines, preferably IL-12 and IL-15. 
     
     
         17 . Use according to anyone of  claims 12 , characterized in that the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration.